COMMUNIQUÉS West-GlobeNewswire

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

30/01/2025 - 22:05

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked [...]

Avid Stockholders Approve Transaction with GHO and Ampersand

30/01/2025 - 22:05

TUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve [...]

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025

30/01/2025 - 22:05

Year-over-year revenue grows 10% , operating profit up 52% , non-GAAP operating profit up 19% Operating cash flow of $309 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at [...]

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

30/01/2025 - 22:05

SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]

Conavi Medical Corp. Announces Proposed Public Offering of Units

30/01/2025 - 22:15

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES TORONTO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“ Conavi Medical ” or the “ [...]

Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

30/01/2025 - 22:30

Conference call scheduled for 8:00 a.m. Eastern Time WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and [...]

Portage Biotech Announces Completion of $2.15 Million Private Financing

30/01/2025 - 22:30

DOVER, Del., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced [...]

Globus Medical Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

30/01/2025 - 22:35

AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31 [...]

Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine

30/01/2025 - 22:37

Diag-Nose.io, a Stanford EENT Innovation graduate, secures $2M in oversubscribed seed funding to revolutionize respiratory care with precise, AI-driven diagnostics and treatment MENLO PARK, Calif., Jan. 30, 2025 (GLOBE [...]

Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI

30/01/2025 - 22:37

Diag-Nose.io launches Houston office to advance precise respiratory care using AI and proteomics after a successful $2M seed round HOUSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Diag-Nose.io, a cutting-edge biotech company [...]

Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics

30/01/2025 - 22:37

Diag-Nose.io sets new standards in respiratory care with AI and proteomics after a $2M seed funding success, now expanding to Bethlehem, PA BETHLEHEM, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- A groundbreaking precision [...]

Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine

30/01/2025 - 22:38

Diag-Nose.io, a CDL-Seattle graduate, harnesses AI with RhinoMAP™ to redefine respiratory care, securing $2M in oversubscribed funding SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- A groundbreaking precision medicine [...]

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

30/01/2025 - 22:57

MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody [...]

LifeMD to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

28/01/2025 - 14:00

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the 12 th Annual BTIG MedTech, Digital Health, Life [...]

Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

28/01/2025 - 14:00

Appoints Simon Harnest as Chief Financial Officer to advance capital markets and corporate development strategy supporting TOS-358, the Company’s lead covalent PI3Kα inhibitor, and additional programs EMERYVILLE, Calif [...]

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

28/01/2025 - 14:00

WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]

Lighthouse Autism Center Announces New Location in South Sioux City, Nebraska, creating 35 Jobs and Serving 25 Families

28/01/2025 - 14:00

Leading ABA Provider Set to Open Newest Location in South Sioux City, NE SOUTH SIOUX CITY, Neb., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Lighthouse Autism Center, South Sioux City, Nebraska, a leading provider of center-based [...]

March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma

28/01/2025 - 14:00

Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating [...]

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

28/01/2025 - 14:01

Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient settings. [...]